China’s Innovent Biologics May Look Into M&As, CFO Says

Feb.04 — Ronnie Ede, executive director and chief financial officer of Jiangsu, China-based Innovent Biologics Inc., which develops and manufactures medicines for diseases such as cancer, discusses the company’s strategy and outlook. Innovent said last month the National Medical Products Administration of China has accepted a supplemental new drug application for sintilimab injection as second-line therapy for lung cancer by the company and Eli Lilly. Ede speaks on “Bloomberg Markets: Asia.”

Articles You May Like

Introducing StockTracker Master Class Volume 1